These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 8479218)

  • 1. [Immunotherapy of leukemia].
    Urbano-Ispizua A; Rozman C
    Med Clin (Barc); 1993 Mar; 100(12):454-6. PubMed ID: 8479218
    [No Abstract]   [Full Text] [Related]  

  • 2. [The role of interleukin-2--based immunotherapy in hematological malignancies].
    Ackerstein A; Toren A; Slavin S; Nagler A
    Harefuah; 1996 May; 130(9):613-7. PubMed ID: 8794642
    [No Abstract]   [Full Text] [Related]  

  • 3. Soluble IL-6 receptors (sIL-6R) in hematological patients receiving immunotherapy with IL-2/IFN-alpha or donor lymphocytes following bone marrow transplantation.
    Toren A; Novick D; Ackerstein A; Or R; Slavin S; Nagler A
    Bone Marrow Transplant; 1996 Oct; 18(4):721-4. PubMed ID: 8899186
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Immunotherapy of acute leukemia].
    Skurkovich SV; Bulycheva TI
    Sov Med; 1978 Aug; (8):26-31. PubMed ID: 705451
    [No Abstract]   [Full Text] [Related]  

  • 5. [Pro and con: Immunotherapy in acute leukemia. Arguments for immunotherapy].
    Büchner T; Urbanitz D
    Internist (Berl); 1980 Jul; 21(7):362-6. PubMed ID: 7007269
    [No Abstract]   [Full Text] [Related]  

  • 6. [Pro and con: Immunotherapy in acute leukemia. Arguments against immunotherapy].
    Hirschmann WD
    Internist (Berl); 1980 Jul; 21(7):367-70. PubMed ID: 7007270
    [No Abstract]   [Full Text] [Related]  

  • 7. [Immunological status change in leukemia patients with infectious complications and during immunotherapy].
    Rozanova LM; Smirnova AI; Shcherbakova EG; Zinkovskaia LN; Eremina TN
    Probl Gematol Pereliv Krovi; 1981 Jan; 26(1):18-20. PubMed ID: 7220515
    [No Abstract]   [Full Text] [Related]  

  • 8. Has IL2 a role in the management of minimal residual disease for acute leukemia?
    Foa R; Meloni G; Guarini A; Mandelli F; Gavosto F
    Leukemia; 1992 Nov; 6 Suppl 4():92-4. PubMed ID: 1434844
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Antigen-presenting cells in cellular immunotherapy].
    Narita M; Furukara T
    Rinsho Ketsueki; 2002 May; 43(5):368-73. PubMed ID: 12096489
    [No Abstract]   [Full Text] [Related]  

  • 10. [Active immunotherapy in the treatment of leukemias].
    Mathé G
    Rev Prat; 1976 May; 26(29):2077-90. PubMed ID: 935773
    [No Abstract]   [Full Text] [Related]  

  • 11. [Blast-cell bank designated for carrying out immunological studies and immunotherapy of leukemia].
    Bulycheva TI; Leontovich VA; Abezgauz NN; Vonograd-Finkel' FR; Agranenko VA
    Probl Gematol Pereliv Krovi; 1977 Feb; (2):32-5. PubMed ID: 877027
    [No Abstract]   [Full Text] [Related]  

  • 12. [PRAME protein expressed in leukemia cells as a target molecule for immunotherapy].
    Ikeda H; Matsushita M; Kawakami H
    Rinsho Ketsueki; 1999 Jun; 40(6):484-6. PubMed ID: 10422284
    [No Abstract]   [Full Text] [Related]  

  • 13. Cytokine modulation of the innate immune system in the treatment of leukemia and lymphoma.
    Farag SS; Caligiuri MA
    Adv Pharmacol; 2004; 51():295-318. PubMed ID: 15464915
    [No Abstract]   [Full Text] [Related]  

  • 14. Histamine dihydrochloride and low-dose interleukin-2 as post-consolidation immunotherapy in acute myeloid leukemia.
    Thorén FB; Romero AI; Brune M; Hellstrand K
    Expert Opin Biol Ther; 2009 Sep; 9(9):1217-23. PubMed ID: 19653866
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vaccines in leukemia.
    Lu S; Wieder E; Komanduri K; Ma Q; Molldrem JJ
    Adv Pharmacol; 2004; 51():255-70. PubMed ID: 15464913
    [No Abstract]   [Full Text] [Related]  

  • 16. [Principal and perspective of adoptive immuno-cell therapy for hematological malignancies].
    Akatsuka Y
    Rinsho Ketsueki; 2007 Oct; 48(10):1328-38. PubMed ID: 17933117
    [No Abstract]   [Full Text] [Related]  

  • 17. [Immunotherapy of hemato-oncologic diseases].
    Winkler U; Bohlen H; Schirrmacher V; Schlimok G; Voliotis D; Brach M; Niederle N; Tesch H; Diehl V; Engert A
    Med Klin (Munich); 1996 Apr; 91(4):226-33. PubMed ID: 8692109
    [No Abstract]   [Full Text] [Related]  

  • 18. Immunological control of human leukemia: discussion.
    Holland JF
    Cancer Res; 1976 Feb; 36(2 pt 2):657-9. PubMed ID: 1253152
    [No Abstract]   [Full Text] [Related]  

  • 19. Adoptive cell-mediated immunotherapy with interleukin-2 (IL-2) for relapsing lymphoblastic crisis following mismatched unrelated bone marrow transplantation in a chronic myelogenous leukemia patient.
    Varadi G; Ackerstein A; Ben-Neriah S; Nagler A
    Bone Marrow Transplant; 1998 Jan; 21(1):93-6. PubMed ID: 9486502
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Extracellular domain of 4-1BBL enhanced the antitumoral efficacy of peripheral blood lymphocytes mediated by anti-CD3 x anti-Pgp bispecific diabody against human multidrug-resistant leukemia.
    Guo H; Jiang W; Liu W; Gao Y; Yang M; Zhou Y; Wang J; Qi J; Cheng X; Zhu Z; Yang C; Xiong D
    Cell Immunol; 2008 Feb; 251(2):102-8. PubMed ID: 18482719
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.